Premium
Combination therapy incorporating Bcl‐2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)
Author(s) -
Gonsalves Wilson I.,
Buadi Francis K.,
Kumar Shaji K.
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12986
Subject(s) - venetoclax , plasma cell leukemia , daratumumab , bortezomib , medicine , oncology , multiple myeloma , plasma cell , salvage therapy , chemotherapy , leukemia , immunology , chronic lymphocytic leukemia
Abstract Primary plasma cell leukemia ( pPCL ) is the most aggressive form of the plasma cell ( PC ) malignancy, multiple myeloma ( MM ). It has been commonly associated with the presence of a chromosome translocation involving the immunoglobulin heavy chain (IgH) locus on 14q32, that is t (11;14). Results from early phase clinical trials utilizing the selective Bcl‐2 inhibitor, venetoclax, as a single agent in patients with relapsed MM have had remarkable efficacy among patients with t (11;14) abnormality. The present case demonstrates the ability of a combination regimen incorporating Bcl‐2 inhibition with daratumumab, bortezomib, venetoclax, and dexamethasone to induce a rapid and very deep hematologic response in a pPCL patient with t (11;14), even in a setting of very refractory disease. This case highlights the need to further study Bcl‐2 inhibition‐based therapy as an option for therapy in patients with pPCL with t (11;14).